ImmunityBio, Inc. IBRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$854.6M-143% | -$351.47M-0.8% | -$348.69M+5.0% | -$367.17M+10.3% | -$409.18M+1.1% | ||
| $16.08M+3.5% | $15.53M-1.7% | $15.8M-3.1% | $16.3M-3.1% | $16.83M-4.1% | ||
| $35.44M-3.7% | $36.81M-0.8% | $37.1M+3.9% | $35.71M0.0% | $35.7M+3.7% | ||
| -$294.39M+3.5% | -$304.94M+4.6% | -$319.7M+8.5% | -$349.56M+5.6% | -$370.16M+5.4% | ||
| $4.5M+17.0% | $3.85M-23.9% | $5.05M-28.9% | $7.11M+5.3% | $6.75M-2.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $0— | ||
| $625.15M+56.2% | $400.24M-11.5% | $452.28M+53.7% | $294.34M+8.8% | $270.42M-4.0% | ||
| —— | —— | —— | —— | —— | ||
| -$298.89M+3.2% | -$308.78M+4.9% | -$324.76M+8.9% | -$356.66M+5.4% | -$376.91M+5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ImmunityBio, Inc. generate?
- ImmunityBio, Inc. (IBRX) generated -$294.4M in operating cash flow over the trailing twelve months.
- What is ImmunityBio, Inc.'s free cash flow?
- After $4.5M of capital expenditures, ImmunityBio, Inc.'s free cash flow was -$298.9M over the trailing twelve months, up 20.7% year over year.
- Where does ImmunityBio, Inc.'s cash flow data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
